Polaryx Therapeutics Receives IND Approval From the FDA to Study PLX-200 Treatment for Patients With Juvenile Neuronal Ceroid Lipofuscinosis |
| April 08, 2020 | April 2020 Bond Updates |
|
PARAMUS, N.J., April 8, 2020 /PRNewswire/ -- Polaryx Therapeutics, a biotech company developing patient-friendly, small molecule therapeutics for lysosomal storage disorders, announced today that the Company has received an Investigational New Drug Application (IND) approval from the U.S.... |
| View more at: https://www.prnewswire.com:443/news-releases/polaryx-therapeutics-receives-ind-approval-from-the-fda-to-study-plx-200-treatment-for-patients-with-juvenile-neuronal-ceroid-lipofuscinosis-301037012.html |
| Related News |
|